Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (MS), a disease that affects more than 2.9 million people globally. The editorial highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS. According to the press release, the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis—in preclinical models.
The advancement of Lucid-MS into Phase 2 trials marks a critical step for Quantum, as it seeks to bring a novel treatment option to the MS community. Current therapies primarily manage symptoms or slow progression, but Lucid-MS aims to directly protect the myelin sheath, potentially offering a disease-modifying approach. For leaders in the biotech and pharmaceutical industries, this development underscores the ongoing shift toward neuroprotective strategies in MS treatment. If successful, Lucid-MS could represent a significant breakthrough, offering hope to millions of patients and opening new avenues for therapeutic intervention.
In addition to its MS program, Quantum has also developed UNBUZZD™, a product aimed at alcohol misuse, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2026. The agreement includes royalty payments of 7% of sales from unbuzzd™ until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop similar products for pharmaceutical and medical uses.
The editorial from BioMedWire, which focuses on the latest developments in the biotechnology, biomedical sciences, and life sciences sectors, provides a platform for Quantum to reach a wide audience of investors, influencers, and industry professionals. This exposure could be pivotal as the company seeks partnerships or funding to advance its clinical pipeline.
For the broader industry, Quantum’s progress highlights the potential of novel chemical entities in addressing complex neurological diseases. Investors and stakeholders should monitor the upcoming Phase 2 trial results, as positive outcomes could validate the approach and catalyze further investment in similar neuroprotective therapies. The full press release is available at https://ibn.fm/KdvrI, and more news about Quantum BioPharma can be found in the company’s newsroom at https://ibn.fm/QNTM.
